We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

43 hedge funds and large institutions have $13.4M invested in NeuBase Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 45 → 43 (-2)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

42% less capital invested

Capital invested by funds: $23.3M → $13.4M (-$9.88M)

Holders
43
Holders Change
-2
Holders Change %
-4.44%
% of All Funds
0.72%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
6
Reduced
7
Closed
7
Calls
$14K
Puts
–
Net Calls
+$14K
Net Calls Change
-$27K

Top Buyers

1
KAS
Kestra Advisory Services
Texas
+$599K
2
CM
CM Management
Florida
+$52.8K
3
JAMONY
Jacob Asset Management of New York
California
+$51.7K
4
Charles Schwab
Charles Schwab
California
+$34.9K
5
Renaissance Technologies
Renaissance Technologies
New York
+$28.5K

Top Sellers

1
Bank of New York Mellon
Bank of New York Mellon
New York
-$164K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$77.4K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$70K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$48K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$34K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$2.86M – – –
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$1.31M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.11M – – –
ACM
4
AIGH Capital Management
Maryland
$1.08M – – –
DCMIC
5
Decheng Capital Management III (Cayman)
Cayman Islands
$1.05M – – –
CMU
6
Carnegie Mellon University
Pennsylvania
$986K – – –
SCM
7
Sio Capital Management
New York
$952K – – –
PAMP
8
Polar Asset Management Partners
Ontario, Canada
$666K – – –
KAS
9
Kestra Advisory Services
Texas
$536K +$599K +25,534 New
JAMONY
10
Jacob Asset Management of New York
California
$494K +$51.7K +2,205 +10%
CM
11
CM Management
Florida
$389K +$52.8K +2,250 +14%
PCM
12
Prelude Capital Management
New York
$327K – – –
Renaissance Technologies
13
Renaissance Technologies
New York
$251K +$28.5K +1,215 +11%
WVP
14
Worth Venture Partners
New Jersey
$249K – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$246K -$11K -470 -4%
Deutsche Bank
16
Deutsche Bank
Germany
$105K – – –
Goldman Sachs
17
Goldman Sachs
New York
$87K +$352 +15 +0.4%
PCM
18
Perkins Capital Management
Minnesota
$86K +$17.6K +750 +23%
WPW
19
Waldron Private Wealth
Pennsylvania
$83K – – –
BlackRock
20
BlackRock
New York
$80K -$258 -11 -0.3%
State Street
21
State Street
Massachusetts
$72K – – –
Northern Trust
22
Northern Trust
Illinois
$58K – – –
TAM
23
Tocqueville Asset Management
New York
$56K – – –
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$51K -$77.4K -3,299 -58%
DC
25
Davenport & Co
Virginia
$48K – – –
1
2

NBSE Hedge Fund Activity: Q2 2022 in Review

43 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2022, worth a combined $13.4M — down 42% from $23.3M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of NBSE and 5 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 6 added.

The largest buyer was Kestra Advisory Services, opening a new position worth an estimated $599K. The largest seller was Bank of New York Mellon, exiting entirely with an estimated $164K sold.

  • 43 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2022, down from 45 in Q1 2022.
  • Funds reported $13.4M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2022, down 42% quarter-over-quarter.
  • 5 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2022 and 7 closed out, a net change of -2 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2022 was Kestra Advisory Services, an estimated $599K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2022 was Bank of New York Mellon, an estimated $164K sold.

Based on aggregated 13F filings for Q2 2022.